Phase 3 data show viral cure rates achieved in a broad range of patients with genotype-1 hepatitis C taking investigational compound faldaprevir plus PegIFN/RBV Multiple studies presented at The Liver MeetingA investigating faldaprevir include difficult-to-cure patient populations, such as those with HIV/HCV coinfection and advanced liver disease ... (more)
http://www.drugs.com/clinical_trials/boehringer-phase-iii-faldaprevir-very-effective-16297.html?
http://www.drugs.com/clinical_trials/boehringer-phase-iii-faldaprevir-very-effective-16297.html?
No comments:
Post a Comment